Aktie 688192 DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Aktien

688192

CNE1000055W8

688192

Schlusskurs Shanghai S.E.
Andere Börsenplätze
 00:00:00 14.05.2024 		% 5 Tage % 1. Jan.
43,08 CNY +3,86 % Intraday Chart für Dizal (Jiangsu) Pharmaceutical Co., Ltd. -4,16 % -9,97 %
29.04. Dizal (Jiangsu) Pharmaceutical Co., Ltd. meldet Ergebnis für das erste Quartal bis zum 31. März 2024 CI
24.04. Dizal (Jiangsu) Pharmaceutical Co., Ltd. kündigt zwei Abstracts mit den neuesten Daten zu Sunvozertinib bei nicht-kleinzelligem Lungenkrebs an CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Dizal Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Dizal Pharmaceutical Co., Ltd. Announces Two Abstracts Featuring the Latest Data on Sunvozertinib in Non-Small Cell Lung Cancer
U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Dizal's Sunvozertinib for the First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
Dizal Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Dizal's Sunvozertinib Pivotal Study Results Published in The Lancet Respiratory Medicine
Dizal Pharmaceutical Co., Ltd.(SHSE:688192) added to Shanghai Stock Exchange Health Care Sector Index
Dizal's Golidocitinib Pivotal Trial Demonstrates Superior and Durable Clinical Benefits for Patients with r/r PTCL in Oral Presentation at 2023 ASH
Dizal Pharma to Invest 700 Million Yuan in New Dermatology Venture
Dizal Pharma Presents Positive Results of Lung Cancer Drug
Dizal Announces Latest Research Findings on the Efficacy and Safety of Sunvozertinib in Treatment-Naive Patients
Chinese Drug Regulator Puts Dizal Pharma's Lymphoma Drug in Priority Review
Dizal Pharmaceutical Receives Priority Review by China NMPA for the Treatment of r/r PTCL
Dizal Pharmaceutical Co., Ltd.(XSSC:688192) added to S&P Global BMI Index
Dizal Pharmaceutical Co., Ltd. Announces China CDE Acceptance of New Drug Application for Golidocitinib for Relapsed or Refractory PTCL
Dizal (Jiangsu) Pharmaceutical's Anti-Lymphoma Medication Research Results Published in European Oncology Journal
Dizal Pharmaceutical Announces Clinical Results of Golidocitinib Published in Annals of Oncology
Anova Enterprises, Inc. Partners with Dizal Pharmaceuticals to Accelerate Development of DZD9008 for Patients with Advanced or Metastatic NSCLC with EGFR Exon20 Insertion Mutation
Dizal Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
Dizal's Sunvozertinib Approves by China NMPA with Potential for Best-In-Class Therapy in NSCLC with EGFR Exon20ins Mutations
Dizal Will Present the Results of Molecular Analysis on EGFR Exon20ins Mutations in Tumor Tissue and Plasma ctDNA
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. 688192 Aktie
  4. Nachrichten Dizal (Jiangsu) Pharmaceutical Co., Ltd.
  5. Andere Sprachen